Pandion Therapeutics and Astellas Pharma have signed a $795m agreement for the research,...
Pandion and Astellas sign deal for Type 1 diabetes bispecifics
Pandion Therapeutics and Astellas Pharma have signed a $795m agreement for the research, development and commercialisation of locally acting immunomodulators to treat Type 1 diabetes, as well as other autoimmune diseases of the pancreas.
Developing drugs for NASH: the race to market
Developing drugs for NASH, a type of liver disease is an emerging field in medicine, which is expected to be extremely lucrative, capturing the imagination of pharma companies and plunging them in a race to market the first drug. Allie Nawrat tracks the race to market currently led by Intercept’s Ocalavia.
US has lowest diagnosis rate for rheumatoid arthritis compared with other major markets
Although it can occur at any age, the disease may start affecting people between the ages of 30 to 60 years.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.